New insider activity at Amedisys ( (AMED) ) has taken place on March 7, 2025.
CAO Allyson Guidroz recently executed a significant transaction by selling 2,041 shares of Amedisys stock. This sale was valued at an impressive $187,833, marking a notable financial move within the company.
Recent Updates on AMED stock
Amedisys Inc reported its Q4 2024 earnings, showing an increase in net service revenue to $598.1 million for the quarter and $2,348.3 million for the year. Despite this growth, the company faced a net loss of $20.4 million in the quarter due to merger-related expenses and a significant impairment charge. The adjusted EBITDA slightly decreased, while adjusted net income per diluted share saw a marginal increase. Amedisys is focused on its strategic merger with UnitedHealth Group, which is expected to enhance service offerings and operational efficiencies. The company announced it would not hold a quarterly earnings call due to the pending merger, which could impact its operations and industry positioning.
More about Amedisys
YTD Price Performance: 1.24%
Average Trading Volume: 414,412
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.02B
Questions or Comments about the article? Write to editor@tipranks.com